uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Angiotensin II, a neuropeptide at frontier between endocrinology and neuroscience:  is there a link between the angiotensin II type 2 receptor andAlzheimer’s disease?
Service of Endocrinology, Department of Medicine, University of Sherbrooke, Canada.
Service of Endocrinology, Department of Medicine, University of Sherbrooke, Canada.
Service of Endocrinology, Department of Medicine, University of Sherbrooke, Canada.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry.
Show others and affiliations
2011 (English)In: Frontiers in Endocrinology, ISSN 1664-2392, Vol. 2, Article 17- p.Article in journal (Refereed) Published
Abstract [en]

Amyloid-β peptide deposition, abnormal hyperphosphorylation of tau, as well as inflammation and vascular damage, are associated with the development of Alzheimer’s disease (AD). Angiotensin II (Ang II) is a peripheral hormone, as well as a neuropeptide, which binds two major receptors, namely the Ang II type 1 receptor (AT1R) and the type 2 receptor (AT2R). Activation of the AT2R counteracts most of the AT1R-mediated actions, promoting vasodilation, decreasing the expression of pro-inflammatory cytokines, both in the brain and in the cardiovascular system. There is evidence that treatment with AT1R blockers (ARBs) attenuates learning and memory deficits. Studies suggest that the therapeutic effects of ARBs may reflect this unopposed activation of the AT2R in addition to the inhibition of the AT1R. Within the context of AD, modulation of AT2R signaling could improve cognitive performance not only through its action on blood flow/brain microcirculation but also through more specific effects on neurons. This review summarizes the current state of knowledge and potential therapeutic relevance of central actions of this enigmatic receptor. In particular, we highlight the possibility that selective AT2R activation by non-peptide and highly selective agonists, acting on neuronal plasticity, could represent new pharmacological tools that may help improve impaired cognitive performance in AD and other neurological cognitive disorders.

Place, publisher, year, edition, pages
2011. Vol. 2, Article 17- p.
National Category
Medicinal Chemistry
Identifiers
URN: urn:nbn:se:uu:diva-191724DOI: 10.3389/fendo.2011.00017OAI: oai:DiVA.org:uu-191724DiVA: diva2:586539
Available from: 2013-01-11 Created: 2013-01-11 Last updated: 2013-01-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Wallinder, CharlottaAlterman, MathiasHallberg, Anders

Search in DiVA

By author/editor
Wallinder, CharlottaAlterman, MathiasHallberg, Anders
By organisation
Organic Pharmaceutical Chemistry
Medicinal Chemistry

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 630 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf